CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zolendronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)

Trial Profile

CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zolendronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Complex regional pain syndromes; Reflex sympathetic dystrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms CREATE-1
  • Sponsors Axsome Therapeutics
  • Most Recent Events

    • 09 May 2017 According to an Axsome Therapeutics media release, readouts are expected in 4Q 2017.
    • 07 Mar 2017 According to an Axsome media release, interim analysis results from study are anticipated in 2H 2017.
    • 14 Nov 2016 According to an Axsome media release, the company anticipate reaching enrollment target of 95 for interim efficacy analysis in the first or second quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top